<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944006</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1160</org_study_id>
    <nct_id>NCT02944006</nct_id>
  </id_info>
  <brief_title>Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling</brief_title>
  <official_title>Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Including DCE-MRI Based on Incoherent Undersampling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish radiomics database for pancreas cancer from multiparametric MRI&#xD;
      including DCE-MRI obtained by using incoherent undersampling and radial acquisition for&#xD;
      clinical staging as well as quantitative analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T-staging</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>T-staging of the tumor at MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N-staging</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>N-staging of the tumor at MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood flow</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>arterial blood flow of the tumor and adjacent parenchma on DCE-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial fraction</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>arterial fraction of the tumor and adjacent parenchyma on DCE-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean transit time</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>mean transit time of the tumor and adjacent parenchyma on DCE-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extracellular volume</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>extracellular volume of the tumor and adjacent parenchyma on DCE-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>true diffusion</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>true diffusion of the tumor and adjacent parenchyma on DWI with intravoxel incoherent motion model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pseudodiffusion</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>pseudodiffusion of the tumor and adjacent parenchyma on DWI with intravoxel incoherent motion model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perfusion fraction</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>perfusion fraction of the tumor and adjacent parenchyma on DWI with intravoxel incoherent motion model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kurtosis</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>kurtosis of the tumor and adjacent parenchyma on DWI with kurtosis model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean diffusivity</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>mean diffusivity of the tumor and adjacent parenchyma on DWI with kurtosis model</description>
  </secondary_outcome>
  <other_outcome>
    <measure>T1 value</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>T1 value of the tumor and adjacent parenchyma using T1 map</description>
  </other_outcome>
  <other_outcome>
    <measure>T2 value</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>T1 value of the tumor and adjacent parenchyma using T2 map</description>
  </other_outcome>
  <other_outcome>
    <measure>fat fraction</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>fat fraction of the tumor and adjacent parenchyma using T2* corrected fat map</description>
  </other_outcome>
  <other_outcome>
    <measure>global textural feature</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>first order parameters related to the grey level frequency distribution in the region of interest using dedicated software</description>
  </other_outcome>
  <other_outcome>
    <measure>local textural feature</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>second order parameters calculated with spatial grey level dependence matrices or co-occurrence matrices using dedicated software</description>
  </other_outcome>
  <other_outcome>
    <measure>attenuation</measure>
    <time_frame>4 weeks after MR acquisition</time_frame>
    <description>hounsefield unit (HU) of the tumor and parameter on CT within 4 weeks of MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>transient dyspnea</measure>
    <time_frame>1 day after MR acquisition</time_frame>
    <description>development of transient dyspnea or involuntary motion after contrast media administration</description>
  </other_outcome>
  <enrollment type="Actual">29</enrollment>
  <condition>Pancreas Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>multi-parametric MRI</intervention_name>
    <description>multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are scheduled to undergo pancreatobiliary MRI as a preoperative workup for&#xD;
        suspected resectable pancreas cancer (adenocarcinoma)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  surgical candidate for pancreatico-duodenectomy&#xD;
&#xD;
          -  characteristic finding of pancreatic adenocarcinoma on prior CT or MRI&#xD;
&#xD;
          -  OR histologically diagnosed with pancreatic adenocarcinoma&#xD;
&#xD;
          -  signed for informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  under 18 years&#xD;
&#xD;
          -  not eligible for pancreatico-duodenectomy&#xD;
&#xD;
          -  unresectable patients (locally advanced on prior CT/MRI or metastatic disease)&#xD;
&#xD;
          -  tumors with suspicion of other histologic types (neuroendocrine, IPMN, etc)&#xD;
&#xD;
          -  any contra-indication of contrast-enhanced MRI&#xD;
&#xD;
          -  recurred pancreatic cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

